- Home
- NKTR vs OLN Comparison
NKTR vs OLN Comparison
Compare NKTR & OLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NKTR | OLN |
|---|---|---|
| Founded | 1990 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NKTR | OLN |
|---|---|---|
| Price | $60.25 | $16.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 13 |
| Target Price | ★ $146.67 | $25.23 |
| AVG Volume (30 Days) | 555.7K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $307,711,000.00 | ★ $6,780,800,000.00 |
| Revenue This Year | N/A | $2.57 |
| Revenue Next Year | N/A | $3.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | 3.68 |
| 52 Week Low | $33.40 | $16.35 |
| 52 Week High | $109.00 | $30.46 |
Technical Indicators
Market Signals| Indicator | NKTR | OLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 40.75 |
| Support Level | $65.14 | $16.73 |
| Resistance Level | $76.63 | $18.29 |
| Average True Range (ATR) | 2.76 | 0.63 |
| MACD | -0.69 | 0.07 |
| Stochastic Oscillator | 3.33 | 30.44 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
About OLN Olin Corporation
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.